By interacting with the p110α catalytic subunit of phosphoinositide 3-kinase (PI3K), KRAS can cause constitutive activation of oncogenic PI3K–protein kinase B (Akt) signaling and promote the progression of lung cancer [18]. This evidence concerns the gene AKT1 and lung cancer.